- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04561453
Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer
A Prospective Feasibility Study of Multi-Platform Profiling Using Biospecimens From Patients With Resected Biliary Tract Cancer
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Gentry King, MD
- Phone Number: 206 606 2494
- Email: gentryk@uw.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Not yet recruiting
- University of Illinois at Chicago
-
Principal Investigator:
- Shikha Jain, MD
-
-
Washington
-
Seattle, Washington, United States, 98195
- Recruiting
- University of Washington
-
Contact:
- Gentry King, MD
- Phone Number: 206-606-2494
- Email: gentryk@uw.edu
-
Principal Investigator:
- Gentry King, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Subjects must meet all of the following criteria to be enrolled in the study:
- Be ≥18 years of age.
- Have a preoperative biopsy with a histopathological diagnosis consistent with a biliary tract cancer (intrahepatic or extrahepatic cholangiocarcinoma or gallbladder carcinoma) or, absent a biopsy, have a clinical presentation consistent with a biliary tract cancer, and are eligible for curative resection
- Surgical candidate for the requisite resection as assessed by a liver surgeon or as assessed by, if deemed necessary, a pre-operative evaluation by internal medicine, cardiology and/or anesthesia.
- Pre-operative imaging showing a measurable amount of disease that, per the judgement of the surgical oncologist, will be enough to allocate to at least genomic profiling as well as the organoid creation portion of this research study.
- Be willing to undergo surgical resection and willing to have the surgery performed at University of Washington.
- Be willing to follow-up with medical oncology post-operatively and allow the study team to collect longitudinal data on their course as well as longitudinal blood samples for circulating tumor DNA surveillance
- Have an ECOG performance status of 0-2.
- Have an expected survival of ≥6 months.
Have adequate bone marrow function as evidenced by:
- Absolute neutrophil count ≥1,000/mm3 or 1.0 ×10^9/L
- Hemoglobin ≥8 g/dL
- Platelets ≥60,000/mm3 or 60 × 10^9/L
Have adequate hepatic function as evidenced by the below, or are expected to have adequate hepatic function (as defined below) post-operatively:
- Serum total bilirubin ≤2 × upper limit of normal (ULN), unless considered due to Gilbert's disease or a biliary obstruction
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤8 × ULN
Have adequate renal function as evidenced by the below or are expected to have adequate renal function (as defined below) post-operatively:
a. Serum creatinine <1.5 × ULN OR b. Creatinine clearance ≥50 mL/min based on the Cockcroft-Gault glomerular filtration rate (GFR) estimation: (140 - Age) x (weight in kg) x (0.85 if female)/72 x sCr
- Be able to understand and willing to sign the informed consent form and to comply with scheduled visits, treatment plans, procedures, and laboratory tests, including serial peripheral blood sampling, during the study.
Exclusion Criteria:
Subjects who meet any of the following criteria will not be enrolled in the study:
- Mixed hepatocellular carcinoma-cholangiocarcinoma on histology.
- Refuses to sign the consent.
- Received any prior systemic targeted therapy (excludes chemotherapy) or an investigational agent directed at their presumed cholangiocarcinoma prior to resection
- Received any prior radiation or catheter-directed therapy to the malignant tumor being resected, unless there has been definitive malignant progression of that tumor since the time of the post-treatment imaging assessment after radiation or catheter-directed therapy.
- Received any systemic anticancer therapy or an investigational agent for another indication (a synchronous cancer of a different primary site) in the 6 months prior to discovery of their presumed cholangiocarcinoma by imaging
- Have known extrahepatic metastases or locally advanced disease precluding resection of the cholangiocarcinoma.
- Have a history of another primary cancer, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid or liquid tumor with no known active disease present that, in the opinion of the Investigator, will not affect subject outcome in the setting of current cholangiocarcinoma diagnosis.
- Are pregnant or breastfeeding
- Have any other acute or chronic medical or psychiatric condition, including recent (within 12 months of cholangiocarcinoma diagnosis) or active suicidal ideation or behavior, or a laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.
- Have been committed to an institution by virtue of an order issued either by the judicial or administrative authorities.
- Are dependent on the Sponsor, Investigator, or study site, per local institution regulations.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Resected Biliary Duct Cancer
|
All patients in the study will have organoid creation and organoid drug sensitivity screening attempted on their fresh tumor tissue from surgical resection.
All patients will also have blood taken pre-operatively and at multiple post-operative time points to monitor circulating tumor DNA.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Success Rate of Organoid Culture and Drug Screen
Time Frame: Within 12 weeks after surgery
|
The investigators will measure the percentage of patients for whom organoids are able to be successfully cultured and subjected to a drug screen.
|
Within 12 weeks after surgery
|
Success Rate of Obtaining circulating tumor DNA (ctDNA) quantification and Ability to assess change in ctDNA levels across those time points
Time Frame: Through study completion, an average of 4 years.
|
The investigators will measure the percentage of patients for whom ctDNA was able to be collected and quantified at multiple key time points across the course of a patient's treatment.
|
Through study completion, an average of 4 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physician-Adjudicated Utility of Profiling Test Results - Post-Adjuvant Therapy
Time Frame: At the time of completion of adjuvant therapy, on average 6 months after surgery.
|
Through surveys, the investigators will ask cancer physicians how helpful the profiling test results are anticipated to be to the ultimate management of the patient after they have received adjuvant chemotherapy.
|
At the time of completion of adjuvant therapy, on average 6 months after surgery.
|
Prospective Concordance of Organoid Drug Screen Results and In Vivo Drug Activity
Time Frame: Through study completion, an average of 4 years.
|
For patients that are treated with drugs that were also evaluated by the initial organoid drug screen, the investigators will measure how often the organoid's response to the drug paralleled the response of the cancer to the drug when administered to the patient.
|
Through study completion, an average of 4 years.
|
Predictive Value of circulating tumor DNA (ctDNA) for Recurrence
Time Frame: From date of randomization until the date of first documented radiographic recurrence, an average of 2 years after surgery.
|
The investigators will evaluate how often measurable post-operative ctDNA levels were able to predict ultimate recurrence of clinical disease.
The investigators will measure the lead time of ctDNA-assessed recurrence over radiographic recurrence.
|
From date of randomization until the date of first documented radiographic recurrence, an average of 2 years after surgery.
|
Concordance of Organoid Drug Screen Results with Next Generation Sequencing (NGS)-Predicted Drug Sensitivities
Time Frame: Within 12 weeks after surgery when results of NGS and Organoid Drug Screen have returned.
|
The investigators will evaluate how often the organoid drug screen responded to a drug that genomic profiling by NGS would have predicted the cancer would be sensitive to.
|
Within 12 weeks after surgery when results of NGS and Organoid Drug Screen have returned.
|
Physician-Adjudicated Utility of Profiling Test Results - At Time of Recurrence
Time Frame: At the time of cancer recurrence, on average 24 months after surgery.
|
Through surveys, the investigators will ask cancer physicians how helpful the profiling test results were to the ultimate management of the patient at the time their cancer recurred.
|
At the time of cancer recurrence, on average 24 months after surgery.
|
Predictive Value of circulating tumor DNA (ctDNA) for Response to Medical Therapy
Time Frame: Through study completion, an average of 4 years.
|
The investigators will correlate ctDNA level trends with radiographic responses to medical treatments.
|
Through study completion, an average of 4 years.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gentry King, MD, University of Washington Seattle Cancer Care Alliance
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Gallbladder Diseases
- Biliary Tract Diseases
- Bile Duct Diseases
- Cholangiocarcinoma
- Klatskin Tumor
- Biliary Tract Neoplasms
- Gallbladder Neoplasms
- Bile Duct Neoplasms
Other Study ID Numbers
- RG1121019
- STUDY00010051 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cholangiocarcinoma
-
M.D. Anderson Cancer CenterActive, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic CholangiocarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Not yet recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic CholangiocarcinomaUnited States
-
RedHill Biopharma LimitedCompletedCholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, IntrahepaticUnited States
-
RedHill Biopharma LimitedAvailableCholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH); CelgeneActive, not recruitingResectable Cholangiocarcinoma | Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8United States
-
National Cancer Institute (NCI)CompletedStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Gallbladder Carcinoma | Metastatic Cholangiocarcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable CholangiocarcinomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)WithdrawnStage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Resectable Intrahepatic Cholangiocarcinoma | Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Stage I Intrahepatic Cholangiocarcinoma AJCC v8United States
-
AIO-Studien-gGmbHServierCompletedCholangiocarcinoma Non-resectable | Cholangiocarcinoma of the Gallbladder | Cholangiocarcinoma Metastatic | Cholangiocarcinoma AdvancedGermany
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma | Advanced CholangiocarcinomaUnited States
-
University of Kansas Medical CenterNational Cancer Institute (NCI)RecruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent CholangiocarcinomaUnited States
Clinical Trials on Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityTerminatedPrimary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditionsUnited States